Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 208 – 20 SEPTEMBER 2024 In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 171/24 and 173/24, respectively. Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Martin Badsted, Chief Financial Officer, tel.: +45 33 42 05 26, e-mail: mba@norden.com

BioStock: WntResearch plummets after results

The initial results from the NeoFox clinical phase II study have arrived. The safety seems to be good, but unfortunately, Foxy-5 appears to have limited treatment effects. The stock plummeted on the news. BioStock contacted Per Norlén, CEO of WntResearch, for a comment.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/wntresearch-plummets-after-results/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

JumpYard announces collaboration with Swedish TV idol Alex Hermansson

He is one of Sweden's most popular TV profiles among kids and young adults, perhaps most well known from the children's show Sommarlov. Alex Hermansson also starred on the hit YouTube series Rackartygarna for more than ten years. Today, JumpYard is proud to announce a collaboration with Alex to bring the joy of movement to children and their families.Alex, also known as "RackarAlex" has been an active athlete, acrobat and gymnast since childhood. Since he became one of Sweden's biggest role models for children and families, he has nurtured a desire to use his influence in a responsible way.

Södra signs agreement to supply UPM with kraft lignin from world-leading new plant

Södra confirms UPM among the first customers for kraft lignin following the major investment announcement earlier this summer regarding kraft lignin production at Södra’s Mönsterås site. The plant is expected to be in operation in 2027, when it will be the first commercial kraft lignin production facility in Sweden and the largest of its type in the world.UPM has a leading position in lignin technologies and markets based on 15 years of intensive development, which has resulted in a strong patent portfolio. Lignin applications are growing fast, driven by market demand for sustainable

UPM Biochemicals and Södra accelerate the commercialisation of innovative lignin-based solutions

(UPM, Helsinki, 20 September at 10:00 EEST) – UPM Biochemicals  will be among the first customers to receive kraft lignin from Södra  when the forest-owner association’s plant in Mönsterås comes on stream in 2027. Södra’s new plant will be the first commercial kraft lignin production facility in Sweden and the largest of its type in the world.   UPM has been innovating with a series of products made from kraft lignin and has successfully marketed this growing portfolio of sustainable lignin solutions over the past

Brain+ A/S announces additional commitments of DKK 1.4 million in the ongoing TO 4 warrant exercise, which is now covered at 40.4%

Copenhagen, Denmark, 20 September 2024 – Brain+ A/S (Nasdaq First North: BRAINP) Brain+ A/S (“Brain+” or “the Company”) has received additional commitments from existing shareholders to exercise warrants of series TO 4 to a combined amount of DKK 1.4 million, covering 26.8% of the total number of outstanding warrants. These include a commitment from the healthtech and digital health specialized German investment boutique, 5P Future of Health Beteiligungs GmbH (“5P Future of Health”), who became a Brain+ shareholder in connection with the Unit Rights Issue earlier this year, to exercise all

Change of Certified Adviser (CA) to Bergs Securities

SpectrumOne AB (publ) hereby announces that the company has entered into an agreement with Bergs Securities AB regarding the service as Certified Adviser. Bergs Securities will take over as Certified Adviser (CA) on 20 September 2024. For further information contact: Fredric Forsman, Chairman+46 739 78 78 44fredric@spectrumone.com Certified Adviser:Aktieinvest FK AB (556072-2596)Box 7415 103 91 StockholmTelefon: +46 8 506 517 03ca@aktieinvest.sewww.aktieinvest.se About SpectrumOne AB SpectrumOne is a leading technology company delivering an advanced Data

Extended Patent Protection for Strangvac approved in the United Kingdom

Stockholm, September 20, 2024 – Intervacc AB (publ) announces that the application for supplementary protection for Strangvac, an innovative vaccine against strangles, has now been approved in the United Kingdom. This supplementary protection extends the existing patent protection from May 2031 to May 2036 on the UK market. The previously approved European patent for Strangvac is valid until May 2031. With the newly granted supplementary protection in the United Kingdom, along with previous applications in other European markets including Sweden, Benelux, Italy, Ireland, France, Spain,

Valmet to supply a new BCTMP line and an evaporator line to JK Paper Limited in India

Valmet Oyj press release, September 20, 2024, at 9:30 a.m. EESTValmet is to supply a new bleached chemi-thermomechanical pulp (BCTMP) line and a related evaporator line to JK Paper Limited’s Fort Songadh mill in India. The new BCTMP line will manufacture high-quality BCTMP pulp for lightweight coated board production. The start-up is scheduled for the end of 2025. The order was included in Valmet's orders received of the second quarter 2024. The value of the order will not be disclosed. “The new BCTMP and evaporator line will play a crucial role in our production process, enabling us

Inflammatory cells in tumour microenvironment promote the transformation of prostate cancer cells into treatment-resistant cells

There is a challenge related to prostate and many other cancers that cancer cells form resistance to treatments as the disease progresses. However, these resistance mechanisms are not yet fully understood. A new study by the University of Eastern Finland found that inflammation-promoting immune cells, M1 macrophages, can transform cancer cells into stem-like cells and thus immune to treatment. The results were published in OncoImmunology journal. The study examined the impact of factors promoting inflammation in a tumour microenvironment on the progression of prostate cancer. Researchers

Notice of Extraordinary General Meeting in Beyond Frames Entertainment AB (publ)

The shareholders in Beyond Frames Entertainment AB (publ), org. no. 559058-8322, are called to an Extraordinary General Meeting at the company's premises on Bondegatan 21, 116 32 in Stockholm on the October 21[st], 2024 at 11:00.The purpose of the Extraordinary General Meeting is to strengthen the Board through the election of a new member and announce resignation from the board. Right to participate and registration The right to participate in the General Meeting has the shareholder who is entered in the share register maintained by Euroclear Sweden AB for the company on October 11,

Alight closes €110 million portfolio senior debt package with Rabobank to finance more solar power in Sweden

Stockholm, Sweden, September 20, 2024 — Alight, a leading Swedish solar independent power producer, is pleased to announce that it has reached the financial close on a senior debt portfolio financing, signed with the Dutch lender Rabobank. The facility gives Alight up to €110 million of financing to build, own and operate roughly 220 MW of small to medium (up to 50 MW) solar parks in Sweden, further strengthening its position in the market.The portfolio facility is thought to be the first of its kind in the Nordics, signifying the maturing market and appetite for lenders to finance the

Joint acquisition of Immedica Pharma completed

Stockholm, September 20, 2024 – KKR, a leading global investment firm, and Impilo, a Nordic healthcare investment firm, have today announced the completion of their joint acquisition of Immedica Pharma, a pharmaceutical company headquartered in Stockholm and focused on the commercialization of medicines for rare diseases and specialty care products. Having announced the strategic partnership in April this year, KKR and Impilo will continue to work together with Immedica’s experienced management team to support the business’ growth, as it continues to build on its position as a leader in

Bioretec’s Shareholders' Nomination Board appointed

Bioretec Ltd   Company announcement      20 September 2024 at 9:00 a.m. (EET)The following persons have been appointed to Bioretec's Shareholders' Nomination Board: Kustaa Poutiainen, Chair and Founder of Stephen Industries Inc Oy as Chair and Karoliina Lindroos, Head of Responsible Investment of Ilmarinen Mutual Pension Insurance Company and Marko Berg, Deputy Investment Officer of University of Helsinki, as members. The Chairman of the Board of Bioretec acts as an expert to the Nomination Board. In accordance with the decision taken by the Annual General Meeting (AGM) held on 26 April

Nightingale Health Plc Financial Statements Release 1 July 2023 – 30 June 2024

Nightingale Health Plc Company release 20 September 2024 at 9:00 a.m. (EEST)   Nightingale Health Group’s Financial Statements Release 1 July 2023 – 30 June 2024 (unaudited)   Nightingale’s Financial Statements Release: Implementation of Nightingale Health’s technology in healthcare is progressing   Nightingale Health maintained strong financial position and reached significant milestones in its core markets Finland, Japan, Singapore, the United Kingdom, and the United States     This release is a summary of Nightingale Health Group’s Financial Statements

Peab signs framework agreement with Vattenfall

ATS Kraftservice AB, which is a subsidiary of Peab, has once again been entrusted as the main contractor for electricity grid services to Vattenfall Eldistribution AB in Central Norrland. The contract runs for three years and is worth SEK 105 million.The project covers Västerbotten County and parts of northern Ångermanland, where the focus of the current project has been on the municipalities of Örnsköldsvik, Nordmaling and Åsele. It is about renewing older electricity networks and strengthening underground cable or overhead line networks. "We are pleased to have Vattenfall's continued

EMA positive opinion for orphan drug designation to Camurus’ octreotide SC depot for the treatment of polycystic liver disease

Lund, Sweden — 20 September 2024 — Camurus (NASDAQ STO: CAMX) today announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has adopted a positive opinion for orphan drug designation (ODD) to the company’s investigational medicinal product, octreotide subcutaneous (SC) depot (CAM2029), for the treatment of autosomal dominant polycystic liver disease (PLD). The European Commission is now assessing the opinion and is expected to grant the designation within 30 days. PLD is a rare, genetic, and chronic disorder characterized by progressive

Notice of AGM

20 September 2024 Marechale Capital plc (“Marechale” or the “Company”) Notice of AGM and Posting of Accounts Marechale Capital plc (AIM: MAC) announces that the Company’s annual report and accounts for the year ended 30 April 2024 and a Notice of Annual General Meeting (“AGM”) have been posted to shareholders of the Company. A copy of the Notice of AGM will shortly be available on the Company’s website, www.marechalecapital.com. The AGM will be held on Tuesday, 15 October 2024 at 12.00 pm at 46 New Broad St., London EC2M 1JH. The Board has made the decision that the AGM will

UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis as a late-breaking oral presentation at the EADV Congress 2024

· ADESOS Phase 2b results with orismilast in atopic dermatitis (AD) selected as late-breaking oral presentation · Additionally, two posters on data from the pioneering use of tape stripping for biomarker analysis in the ADESOS study and additional ADESOS Phase 2b results · Orismilast is a next generation, high potency PDE4 B/D selective inhibitor with reported positive results from a Phase 2b study in psoriasis and Phase 2, IIT, study in hidradenitis suppurativa (HS); orismilast is currently being evaluated in an ongoing Phase 2, IIT study in ulcerative colitis (UC) · UNION plan to

MPCC: Fixed income investor meetings

Oslo, Norway - MPC Container Ships ASA (the "Company") has mandated Arctic Securities and Pareto Securities as Joint Global Coordinators and Joint Bookrunners to arrange a series of fixed income investor meetings commencing Monday 23 September. A new USD denominated 5-year sustainability-linked senior unsecured bond issue may follow, subject to inter alia market conditions. The net proceeds from the contemplated bond issue shall be applied towards general corporate purposes of the Group, including refinancing of existing financial indebtedness and acquisition of maritime assets.

Husqvarna AB’s Nomination Committee for the 2025 Annual General Meeting

The members of the Nomination Committee for the Husqvarna AB 2025 Annual General Meeting (“AGM”) have now been appointed, as follows:Petra Hedengran (Chair, appointed by Investor AB) Louise Lindh (appointed by L E Lundbergföretagen AB) Fredrik Ahlin (appointed by If Skadeförsäkring AB) Oskar Börjesson (appointed by Livförsäkringsbolaget Skandia) Tom Johnstone (Board Chair of Husqvarna AB)   Such appointments have been made in accordance with the rules last approved by the Husqvarna AB AGM. Those rules state that the Nomination Committee shall consist of one representative

Tietoevry: Ex-dividend

Tietoevry Corporation               STOCK EXCHANGE RELEASE               20 September 2024   8.00 a.m. EEST   The Annual General Meeting held on 13 March 2024 decided on a total dividend of EUR 1.47 per share to be paid in two instalments.   From today 20 September 2024, the shares in Tietoevry (Nasdaq Helsinki: TIETO, Nasdaq Stockholm: TIETOS, Oslo Børs: TIETO) will be traded excluding the right to the second dividend instalment of EUR 0.735 per share.   This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading

There are no items matching the current filter
There are no more items matching the current filter
Back to top